Understanding the Immune System's Role in Acne
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
This research explores how our body's immune cells fight the bacteria that cause acne, hoping to find new ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11123418 on NIH RePORTER |
What this research studies
Acne is a common skin condition often linked to a specific type of bacteria called Cutibacterium acnes. Our immune system has special cells, called TH17 cells, that can release 'traps' to kill these bacteria. We've found that different types of C. acnes bacteria can change how these immune cells behave, either helping or hindering their ability to fight infection. This project aims to understand exactly how these immune traps work in acne and how the bacteria influence them. By uncovering these mechanisms, we hope to discover new targets for future acne treatments.
Who could benefit from this research
Good fit: Patients with acne vulgaris who are interested in contributing to basic science research that could inform future therapies might find this work relevant.
Not a fit: Patients seeking immediate new treatments or direct clinical intervention will not receive benefit from this foundational research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments for acne that target the immune system or use beneficial bacteria, offering more effective ways to manage the condition.
How similar studies have performed: While the role of TH17 cells and C. acnes in acne has been previously observed, the specific mechanisms of T cell extracellular trap formation and their biological impact in acne are currently unknown, making this a novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Agak, George W — University of California Los Angeles
- Study coordinator: Agak, George W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.